Abstracts tagged "gout"

Abstract Number: 1139 • 2017 ACR/ARHP Annual Meeting
Management of Gout – a Survey for Healthcare Providers in South Australia
Nieves Leonardo¹ and Julian McNeil², ¹Rheumatology, The Queen Elizabeth Hospital, Woodville South, Australia, ²Rheumatology, Northern Adelaide Local Health Network, Modbury, Australia
Background/Purpose: Gout is a treatable arthritis and while the rate of gout in Australia has been steadily rising, drugs used to treat acute gouty arthritis…
Abstract Number: 2077 • 2017 ACR/ARHP Annual Meeting
Statin Use and Mortality in Gout: A General Population-Based Cohort Study
Sarah Keller¹, Sharan K. Rai², Na Lu¹, Amar Oza³, Yuqing Zhang⁴ and Hyon K. Choi², ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Although the cardinal feature of gout is inflammatory arthritis, it is also a metabolic condition closely associated with an elevated uric acid burden and…
Abstract Number: 1090 • 2017 ACR/ARHP Annual Meeting
A Multidisciplinary Performance Improvement Approach to Achieving Goal Serum Uric Acid Levels in Patients with Gout
Luke Monteagudo¹, Jefferson Roberts², Donna Kido³, Collette Chin³ and Susan Fujii³, ¹Internal Medicine, Tripler Army Medical Center, Honolulu, HI, ²Rheumatology, Tripler Army Medical Center, Honolulu, HI, ³Pharmacy, Tripler Army Medical Center, Honolulu, HI
Background/Purpose: In patients with gout, hyperuricemia leads to inflammation induced by mono-sodium urate crystal deposition. This causes irreversible physical and radiographically evident destruction of the…
Abstract Number: 1864 • 2017 ACR/ARHP Annual Meeting
Longitudinal Changes in Serum Uric Acid Levels and Associated Risk of Cardiometabolic Events and Renal Insufficiency in Gout Patients
Rishi J. Desai¹, Jessica Franklin², Julia Spoendlin², Goodarz Danaei³, Daniel H. Solomon⁴ and Seoyoung C. Kim⁵, ¹PharmacoEpidemiology & PharmacoEconomics, Brigham & Women's Hospital, Boston, MA, ²Brigham & Women's Hospital, Boston, MA, ³Harvard School of Public Health, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Gout patients have an increased risk of type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), and chronic kidney disease (CKD); however, it is not…
Abstract Number: 2078 • 2017 ACR/ARHP Annual Meeting
Hypersensitivity Reactions with Allopurinol and Febuxostat in Adults 65 Years or Older: A Study Using the Medicare Claims Data
Jasvinder A. Singh¹ and John Cleveland², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology, University of Alabama at Birmingham (UAB), Birmingham, AL
Background/Purpose: Clinicians using allopurinol are always concerned about the risk of rare hypersensitivity reaction. Allopurinol and febuxostat are the two most common urate-lowering agents used…
Abstract Number: 1107 • 2017 ACR/ARHP Annual Meeting
An Illness By Any Other Name: The Effect of Changing the Disease Label of Gout on the Perceptions of the Illness and Its Management
Keith Petrie¹, Kate MacKrill¹, Christina Derksen² and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²University of Marburg, Marburg, Germany
Background/Purpose: Gout is a chronic disease caused by deposition of monosodium urate crystals. Although diet is a risk factor, many other factors also contribute to…
Abstract Number: 2052 • 2017 ACR/ARHP Annual Meeting
Apply Musculoskeletal Ultrasonography to Predict Chronic Gouty Arthritis in Patients with Chronic Kidney Diseases
Zheng-Hao Huang¹, Chi-Ching Chang², En Chao³, Hui-Hsun Chiang⁴, Shu-Yi Lin⁵, Kun-Lin Wu⁶, Hsiang-Cheng Chen⁵, Shi-Jye Chu⁵, San-Yuan Kao⁵, Tsung-Yun Hou⁵, Feng-Cheng Liu⁵, Chen-Hung Chen⁷, Deh-Ming Chang⁸ and Chun-Chi Lu⁹, ¹Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, Kaohsiung Armed Forces General Hospital; Tri-service general hospital, National Defense Medical Center, Taipei, Taiwan, ²Taipei Medical University Hospital, Taipei, Taiwan, ³Tri-Service General Hospital Songshan Branch, Taipei, Taiwan, ⁴School of Nursing, National Defense Medical Center, Taipei, Taiwan, ⁵Tri-Service General Hospital, Taipei, Taiwan, ⁶Armed Forces Taoyuan General Hospital, Taipei, Taiwan, ⁷Taipei Tzu Chi hospital, Taipei, Taiwan, ⁸Taipei Veterans General Hospital, Taipei, Taiwan, ⁹University of Washington; Tri-Service General Hopsital, National Defense Medical Center, Seattle, WA
Background/Purpose: Gouty arthritis, caused by the deposition of monosodium urate (MSU) monohydrate crystals at joints, is comprised of multiple inflammatory processes in synovium, tendons, cartilages…
Abstract Number: 2084 • 2017 ACR/ARHP Annual Meeting
Patients with Early Onset Gout Develop Earlier Severe Joint Involvement and Metabolic Comorbid Conditions
Tristan Pascart¹, Laurène Norberciak², Hang-Korng Ea³, Sabine Lanz⁴, Charles Lambert⁵, Pascal Guggenbuhl⁶ and Frederic Liote⁷, ¹Rheumatology, Lille Catholic University, Lille, France, ²Lille Catholic University, Lille, France, ³INSERM UMR1132, Paris Diderot University, Paris, France, ⁴Laboratoire Mayoli Spindler, Chatou, France, ⁵Laboratoire Ipsen Pharma, Boulogne, France, ⁶Rennes University, Rennes, France, ⁷University Paris Diderot, Paris, France
Patients with Early Onset Gout develop Earlier Severe Joint Involvement and Metabolic Comorbid Conditions Background/Purpose: Early onset gout might encompass more severe cases along with genetic defects,…
Abstract Number: 1108 • 2017 ACR/ARHP Annual Meeting
Effect of Body Mass Index on Serum Urate and Renal Uric Acid Handling Responses to an Oral Inosine Load
Nicola Dalbeth¹, Jordyn de Kwant¹, Gregory Gamble², Amanda Phipps-Green³, Anne Horne², Lisa K. Stamp⁴ and Tony R. Merriman⁵, ¹University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Increased body mass index (BMI) is an important risk factor for hyperuricemia and gout. It is unknown whether overweight and obesity influences serum urate…
Abstract Number: 2056 • 2017 ACR/ARHP Annual Meeting
Performance and Validity of Musculoskeletal Ultrasound in the Assessment of Synovial Inflammation in Experimental Acute Gout
Raquel Largo¹, Juan Pablo Medina², Sandra Perez-Baos², Victor Najera-Aleson², Aranzazu Mediero², Gabriel Herrero-Beaumont¹ and Esperanza Naredo³, ¹Bone and Joint Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain, ²Joint and Bone Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain, ³Rheumatology, Joint and Bone Research Unit, IIS-FJD, Hospital Universitario Fundación Jiménez Díaz., Madrid, Spain
Background/Purpose: Musculoskeletal ultrasound (MS-US) has not been validated as a reliable technique to evaluate joint inflammation in an acute gout rabbit model. Rabbit has been…
Abstract Number: 2087 • 2017 ACR/ARHP Annual Meeting
Allelic Variants of ABCG2 and Gout Risk
Blanka Stiburkova^1,2, Katerina Pavelcova^2,3, Jakub Zavada², Lenka Petru^2,3, Marketa Pavlikova^2,4, Hirotaka Matsuo⁵, Tony R. Merriman⁶ and Karel Pavelka⁷, ¹Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Department of probability and mathematical statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic, ⁵Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, Japan, ⁶Department of Biochemistry, University of Otago, Dunedin, New Zealand, ⁷Institute of Rheumatology, Praha, Czech Republic
Background/Purpose: Common dysfunctional variants of ABCG2, a high-capacity urate transporter gene, that result in decreased urate excretion, are major causes of hyperuricemia and gout. In…
Abstract Number: 1111 • 2017 ACR/ARHP Annual Meeting
Protective Effect of Allopurinol Use on Kidney Function Among Patients with Gout and Chronic Kidney Disease
Ana Beatriz Vargas-Santos¹, Christine Peloquin², Yuqing Zhang^3,4 and Tuhina Neogi⁴, ¹Internal Medicine - Rheumatology, State University of Rio de Janeiro, Rio de Janeiro, Brazil, ²Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: There is increasing evidence that allopurinol may be protective of kidney function among hyperuricemic subjects, though clinicians are often cautious about using allopurinol in…
Abstract Number: 2057 • 2017 ACR/ARHP Annual Meeting
Identification of Urate Deposits in Patients with Asymptomatic Hyperuricemia Using a Dual-Energy CT Scan
Penny Wang¹, Stacy Smith², Rajesh Garg³, Fengxin Lu¹, Alyssa Wohlfahrt¹, Anarosa Campos¹, Kathleen Vanni⁴, Zhi Yu⁵, Daniel H. Solomon¹ and Seoyoung C. Kim¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Radiology, Division of Musculoskeletal Imaging and Intervention, Brigham and Women's Hospital, Boston, MA, ³Division of Endocrinology, Diabetes & Hypertension, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Serum uric acid (sUA) is a useful indicator of the risk of developing gout. However, most patients with elevated sUA levels do not have…
Abstract Number: 2091 • 2017 ACR/ARHP Annual Meeting
Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with Svp-Rapamycin Enables Sustained Reduction of Serum Uric Acid Levels By Mitigating Formation of Anti-Drug Antibodies
Earl Sands¹, Alan J. Kivitz², Wesley DeHaan Ph.D.¹, Lloyd Johnston¹ and Takashi Kei Kishimoto¹, ¹Selecta Biosciences, Watertown, MA, ²Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Pegylated uricases are promising therapies for the treatment of severe chronic gout, particularly for the rapid resolution of tophi. However uricases are limited…
Abstract Number: 1112 • 2017 ACR/ARHP Annual Meeting
Efficacy of High Dose Versus Moderate Dose Prednisone in the Treatment of Acute Gout
Rochella A. Ostrowski¹, Elizabeth Araujo², Richard Hariman³ and Elaine Adams⁴, ¹Division of Rheumatology, Loyola University Medical Center, Maywood, IL, ²Rheumatology and Immunology, Department of Internal Medicine 3, Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ³Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁴Rheumatology, Edward Hines Jr Hospital, Veterans Administration, Hines, IL
Background/Purpose: Despite the use of corticosteroids in acute gout, there exist wide variations in treatment doses and duration. No studies have evaluated the ideal dose…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].